Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096317151> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3096317151 endingPage "154" @default.
- W3096317151 startingPage "154" @default.
- W3096317151 abstract "Background: Infections with hepatitis B virus (HBV) continue to be a worldwide problem and a considerable proportion of these infections usually progress to chronic infection and hepatocellular carcinoma. The available treatments of HBV infections include interferon- alpha (IFN-a) and nucleoside analogue agents (lamivudine, adefovir, entecavir, telbivudine, and others). it has become increasingly evident that lamivudine- resistant mutations occur naturally and exist in HBV carriers who have not received lamivudine therapy. The HBV isolates in Libya have not been characterized in terms of lamivudine drug resistance. Methods: One hundred and fi fteen clinical plasma specimens of HBV infected patients were collected and HBV-DNA quantifi cation were performed in all specimens by Rotor- Gene 3000™. INNO-LiPA HBV Drug assay were applied for HBV drug resistance in 57 isolates. All isolates were collected at Saint James medical Laboratory, Tripoli, where HBV-DNA quantity and HBV drug resistance were performed. Questionnaires completed for each patient including personal data (name, address, gender, age and nationality) and the “RoboGene HBV Quantifi cation Kits” allows both standardized purifi cation and real-time in vitro quantifi cation of HBV-DNA isolates via amplifi cation of a subsequence of the viral gene coding for the HBsAg. Results: This study was conducted during the period from August 20, 2009 to February 25, 2010. Serum samples were collected from 115 patients, 74 (64.3%) males and 41 (35.7%) females. Conclusions: HBV DNA polymerase has an activity of reversed transcription and a highly conservative YMDD order locating in the polymerase structural region C area, which is the combing and functioning site of LAM (nucleoside antiviral medicine). Lamivudine-resistant HBV strains with YMDD mutations are an important factor for the failure of chronic hepatitis B treatment. Although emergence of drug-resistant strains is closely related to the duration of the lamivudine treatment." @default.
- W3096317151 created "2020-11-09" @default.
- W3096317151 creator A5000650115 @default.
- W3096317151 date "2014-01-01" @default.
- W3096317151 modified "2023-09-23" @default.
- W3096317151 title "Poster Session : PS 0412 ; Infectious Disease ; Prevalence of Lamivudine Drug Resistance among Hepatitis B Virus Untreated Patients" @default.
- W3096317151 hasPublicationYear "2014" @default.
- W3096317151 type Work @default.
- W3096317151 sameAs 3096317151 @default.
- W3096317151 citedByCount "0" @default.
- W3096317151 crossrefType "journal-article" @default.
- W3096317151 hasAuthorship W3096317151A5000650115 @default.
- W3096317151 hasConcept C114851261 @default.
- W3096317151 hasConcept C159047783 @default.
- W3096317151 hasConcept C2522874641 @default.
- W3096317151 hasConcept C2776175608 @default.
- W3096317151 hasConcept C2777382497 @default.
- W3096317151 hasConcept C2777410769 @default.
- W3096317151 hasConcept C2777869810 @default.
- W3096317151 hasConcept C2779517838 @default.
- W3096317151 hasConcept C2780593183 @default.
- W3096317151 hasConcept C2781144229 @default.
- W3096317151 hasConcept C71924100 @default.
- W3096317151 hasConcept C86803240 @default.
- W3096317151 hasConcept C89423630 @default.
- W3096317151 hasConceptScore W3096317151C114851261 @default.
- W3096317151 hasConceptScore W3096317151C159047783 @default.
- W3096317151 hasConceptScore W3096317151C2522874641 @default.
- W3096317151 hasConceptScore W3096317151C2776175608 @default.
- W3096317151 hasConceptScore W3096317151C2777382497 @default.
- W3096317151 hasConceptScore W3096317151C2777410769 @default.
- W3096317151 hasConceptScore W3096317151C2777869810 @default.
- W3096317151 hasConceptScore W3096317151C2779517838 @default.
- W3096317151 hasConceptScore W3096317151C2780593183 @default.
- W3096317151 hasConceptScore W3096317151C2781144229 @default.
- W3096317151 hasConceptScore W3096317151C71924100 @default.
- W3096317151 hasConceptScore W3096317151C86803240 @default.
- W3096317151 hasConceptScore W3096317151C89423630 @default.
- W3096317151 hasIssue "1" @default.
- W3096317151 hasLocation W30963171511 @default.
- W3096317151 hasOpenAccess W3096317151 @default.
- W3096317151 hasPrimaryLocation W30963171511 @default.
- W3096317151 hasRelatedWork W149533228 @default.
- W3096317151 hasRelatedWork W1509444392 @default.
- W3096317151 hasRelatedWork W1965115572 @default.
- W3096317151 hasRelatedWork W2002897380 @default.
- W3096317151 hasRelatedWork W2089142573 @default.
- W3096317151 hasRelatedWork W2099487357 @default.
- W3096317151 hasRelatedWork W2117255254 @default.
- W3096317151 hasRelatedWork W2126043020 @default.
- W3096317151 hasRelatedWork W2300241505 @default.
- W3096317151 hasRelatedWork W2358535063 @default.
- W3096317151 hasRelatedWork W2387565984 @default.
- W3096317151 hasRelatedWork W2467229759 @default.
- W3096317151 hasRelatedWork W2597959960 @default.
- W3096317151 hasRelatedWork W2893706454 @default.
- W3096317151 hasRelatedWork W2898100667 @default.
- W3096317151 hasRelatedWork W2990025383 @default.
- W3096317151 hasRelatedWork W3013508326 @default.
- W3096317151 hasRelatedWork W3030104605 @default.
- W3096317151 hasRelatedWork W3160891930 @default.
- W3096317151 hasRelatedWork W3112845783 @default.
- W3096317151 hasVolume "2014" @default.
- W3096317151 isParatext "false" @default.
- W3096317151 isRetracted "false" @default.
- W3096317151 magId "3096317151" @default.
- W3096317151 workType "article" @default.